I thought about busting the PS out of the attic recently just for Spyro and Crash Bandicoot

my linkedin feed has become filled with psychedelic memes and I'm connected with an OG acid kingpin.

Thanks Parker!

Analiese Lahey, @pimcuijpers.bsky.social, @mathiasharrer.bsky.social, @mntj21.bsky.social, Sandeep Nayak, Eric Strain, @vandyatvandy.bsky.social, Bob Dworkin, @jcobbscott.bsky.social. @ted-satterthwaite.bsky.social, @pennlinc.bsky.social

All of this and more can be easily accessed through sypres.io

Team effort with co-first author (!!!) @bsevchik.bsky.social and the rest of the SYPRES and Metapsy team who made this happen!

In partnership with metapsy.org we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports

Dashboard: metapsy.org/sypres/psilo...

Our database includes 200+ effect sizes, encompassing all depression outcomes and timepoints reported by arm in each of the 12 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R environments using the metapsyData package from metapsy.org

Here, psilocybin showed a greater reduction in depression scores compared to control conditions, with a pooled Hedges’ g = -0.91 (k = 9; p = 0.0013, I2 = 58.1%, n = 501). But important caveats—small studies, blinding challenges, risk of bias, and design heterogeneity, which we discuss in the paper.

sypres.io is our new initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data

Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living, evidence synthesis that is visible and accessible to all stakeholders.